Anti-Hemagglutinin Antibody Compositions and Methods of Use Thereof

1 . An isolated fully human monoclonal antibody, wherein said monoclonal antibody has the following characteristics:

a) binds to an influenza A virus;

b) binds to a cell contacted with influenza A;

c) binds to an epitope of an influenza A viral protein; and

d) neutralizes influenza A virus infection.

2 . The antibody of claim 1 , wherein said influenza A viral protein is hemagglutinin (HA).

3 . The antibody of claim 2 , wherein said hemagglutinin (HA) comprises a hemagglutinin precursor peptide (HA0), a HA1 subunit, a HA2 subunit, a mature protein containing HA1 and HA2, or a recombinant HA polypeptide.

4 . The antibody of claim 3 , wherein recombinant HA polypeptide is encoded by the sequence of SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19.

5 . The antibody of claim 1 , wherein said antibody is isolated from a B-cell that is isolated from a human donor.

6 . The antibody of claim 1 , wherein said epitope is linear or non-linear.

7 . The antibody of claim 6 , wherein said non-linear epitope is a discontinuous epitope.

8 . The antibody of claim 1 , wherein said antibody is (a) TCN-522 (3212_I12), TCN-521 (3280_D18), TCN-523 (5248_A17), TCN-563 (5237_B21), TCN-526 (5084_C17), TCN-527 (5086_C06), TCN-528 (5087_P17), TCN-529 (5297_H01), TCN-530 (5248_H10), TCN-531 (5091_H13), TCN-532 (5262_H18), TCN-533 (5256_A17a), TCN-534 (5249_B02), TCN-535 (5246_P19), TCN-536 (5095_N01), TCN-537 (3194_D21), TCN-538 (3206_O17), TCN-539 (5056_A08), TCN-540 (5060_F05), TCN-541 (5062_M11), TCN-542 (5079_A16), TCN-543 (5081_G23), TCN-544 (5082_A19), TCN-545 (5082_I15), TCN-546 (5089_L08), TCN-547 (5092_F11), TCN-548 (5092_P01), TCN-549 (5092_P04), TCN-550 (5096_F06), TCN-551 (5243_D01), TCN-552 (5249_I23), TCN-553 (5261_C18), TCN-554 (5277_M05), TCN-555 (5246_L16), TCN-556 (5089_K12), TCN-557 (5081_A04), TCN-558 (5248_H10b), TCN-559 (5097_G08), TCN-560 (5084_P10), TCN-564 (5256_A17b), or TCN-504 (3251_K17), or (b) an antibody that binds the same epitope as TCN-522 (3212_I12), TCN-521 (3280_D18), TCN-523 (5248_A17), TCN-563 (5237_B21), TCN-526 (5084_C17), TCN-527 (5086_C06), TCN-528 (5087_P17), TCN-529 (5297_H01), TCN-530 (5248_H10), TCN-531 (5091_H13), TCN-532 (5262_H18), TCN-533 (5256_A17a), TCN-534 (5249_B02), TCN-535 (5246_P19), TCN-536 (5095_N01), TCN-537 (3194_D21), TCN-538 (3206_O17), TCN-539 (5056_A08), TCN-540 (5060_F05), TCN-541 (5062_M11), TCN-542 (5079_A16), TCN-543 (5081_G23), TCN-544 (5082_A19), TCN-545 (5082_I15), TCN-546 (5089_L08), TCN-547 (5092_F11), TCN-548 (5092_P01), TCN-549 (5092_P04), TCN-550 (5096_F06), TCN-551 (5243 D01), TCN-552 (5249_I23), TCN-553 (5261_C18), TCN-554 (5277_M05), TCN-555 (5246_L16), TCN-556 (5089_K12), TCN-557 (5081_A04), (5248_H10b), TCN-559 (5097_G08), TCN-560 (5084_P10), TCN-564 (5256_A17b), or TCN-504 (3251_K17).

9 . An isolated anti-hemagglutinin (HA) antibody, wherein said antibody comprises a combination of variable heavy chain complementarity determining region 1 (VH CDR1), variable heavy chain complementarity determining region 2 (VH CDR2), variable heavy chain complementarity determining region 3 (VH CDR3), variable light chain complementarity determining region 1 (VL CDR1), variable light chain complementarity determining region 2 (VL CDR2), and variable light chain complementarity determining region 3 (VL CDR3), selected from the group consisting of:

(a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 511;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 512,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 513,

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 517;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 181, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 518;

(b) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 22;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 23,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 24,

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 29;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 30, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 31;

(c) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 34;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 35,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 36,

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 41;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 42, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 43;

(d) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 46;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 47,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 48,

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 53;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 54, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 55;

(e) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 62;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 58,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 59,

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 65;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 66, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 67;

(f) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 70;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 71,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 72,

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 77;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 78, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 79;

(g) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 82;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 83,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 84,

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 89;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 90, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 91;

(h) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 94;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 95,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 96,

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 101;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 102, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 103;

(i) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 106;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 107,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 108,

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 113;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 114, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 115;

(j) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 118;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 119,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 120,

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 125;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 126, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 127;

(k) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 130;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 131,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 132,

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 137;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 138, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 139;

(l) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 142;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 143,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 144,

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 149;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 150, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 151;

(m) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 154;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 155,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 156,

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 53;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 54, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 55;

(n) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 162;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 163,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 164,

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 169;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 170, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 171;

(o) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 174;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 175,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 176,

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 157;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 181, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 182;

(p) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 185;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 186,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 187,

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 192;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 30, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 193;

(q) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 196;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 197,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 198,

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 203;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 204, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 205;

(r) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 208;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 209,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 210,

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 215;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 216, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 217;

(s) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 220;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 221,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 222,

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 227;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 228, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 229;

(t) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 232;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 233,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 234;

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 239;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 240, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 241;

(u) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 244;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 245,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 246;

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 251;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 252, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 253;

(v) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 256;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 257,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 258;

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 263;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 264, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 265;

(w) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 268;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 269,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 270;

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 275;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 276, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 277;

(x) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 280;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 281,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 282;

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 287;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 288, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 289;

(y) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 292;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 293,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 294;

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 299;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 181, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 300;

(z) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 303;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 304,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 305;

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 310;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 30, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 311;

(aa) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 314;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 315,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 316;

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 321;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 322, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 323;

(bb) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 303;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 326,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 327;

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 332;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 216, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 333;

(cc) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 336;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 337,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 338;

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 343;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 216, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 344;

(dd) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 347;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 348,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 349;

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 354;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 355, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 356;

(ee) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 359;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 360,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 361;

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 366;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 367, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 368;

(ff) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 371;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 372,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 373;

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 378;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 379, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 380;

(gg) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 383;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 384,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 385;

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 203;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 181, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 390;

(hh) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 393;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 394,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 395;

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 400;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 216, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 401;

(ii) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 62;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 58,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 59;

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 406;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 66, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 67;

(jj) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 409;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 410,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 411;

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 416;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 417, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 418;

(kk) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 421;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 422,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 423;

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 428;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 429, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 430;

(ll) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 174;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 175,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 176;

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 125;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 126, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 127;

(mm) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 435;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 436,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 437;

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 442;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 443, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 444;

(nn) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 447;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 448,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 449;

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 454;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 455, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 456; and

(oo) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 154;

a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 155,

a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 156;

a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 520;

a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 521, and

a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 522.

10 . An isolated fully human monoclonal anti-hemagglutinin (HA) antibody comprising:

a) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 510 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 524 or

b) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 21 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 28 or

c) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 33 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 40 or

d) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 45 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 52 or

e) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 57 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 64 or

f) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 69 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 76 or

g) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 81 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 88 or

h) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 93 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 100 or

i) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 105 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 112 or

j) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 117 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 124 or

k) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 129 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 136 or

l) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 141 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 148 or

m) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 153 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 52 or

n) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 161 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 168 or

o) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 173 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 180 or

p) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 184 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 191 or

q) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 195 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 202 or

r) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 207 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 214 or

s) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 219 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 226 or

t) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 231 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 238 or

u) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 243 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 250 or

v) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 255 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 262 or

w) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 267 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 274 or

x) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 279 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 286 or

y) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 291 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 298 or

z) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 302 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 309 or

aa) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 313 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 320 or

bb) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 325 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 331 or

cc) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 335 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 342 or

dd) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 346 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 353 or

ee) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 358 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 365 or

ff) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 370 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 377 or

gg) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 382 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 389 or

hh) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 392 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 399 or

ii) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 403 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 405 or

jj) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 420 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 427 or

kk) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 173 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 124 or

ll) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 434 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 441 or

mm) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 446 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 453 or

nn) a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 153 and a light chain variable sequence comprising amino acid sequence SEQ ID NO: 519.

11 . The antibody of claim 1 , wherein said cell is a eukaryotic cell.

12 . The antibody of claim 1 , wherein said cell is a human cell.

13 . The antibody of claim 1 , wherein said antibody is operably-linked to a therapeutic agent or a detectable label.

14 . A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutical carrier.

15 . The composition of claim 14 , further comprising an anti-viral drug, a viral entry inhibitor or a viral attachment inhibitor.

16 . The composition of claim 15 , wherein said anti-viral drug is a neuraminidase inhibitor, a HA inhibitor, a sialic acid inhibitor or an M2 ion channel inhibitor.

17 . The composition of claim 16 , wherein said M2 ion channel inhibitor is amantadine or rimantadine.

18 . The composition of claim 16 , wherein said neuraminidase inhibitor zanamivir or oseltamivir phosphate.

19 . The composition of claim 14 , further comprising a second anti-Influenza A antibody.

20 . A method for stimulating an immune response in a subject, comprising administering to the subject the pharmaceutical composition of claim 14 .

21 . A method for the treatment of an Influenza virus infection in a subject, comprising administering to the subject the pharmaceutical composition of claim 14 .

22 . A method for the prevention of an Influenza virus infection in a subject, comprising administering to the subject the composition of claim 14 prior to exposure of the subject to Influenza virus or infection.

23 . The method of claim 21 , wherein the method further comprises administering an anti-viral drug, a viral entry inhibitor, a viral attachment inhibitor, or a second anti-Influenza A antibody.

24 . The method of claim 23 , wherein said anti-viral drug is a neuraminidase inhibitor, a HA inhibitor, a sialic acid inhibitor or an M2 ion channel.

25 . The method of claim 24 , wherein said M2 ion channel inhibitor is amantadine or rimantadine.

26 . The method of claim 24 , wherein said neuraminidase inhibitor zanamivir or oseltamivir phosphate.

27 . The method of claim 21 , wherein said antibody is administered prior to or after exposure to Influenza virus.

28 . The method of claim 21 , wherein said antibody is administered at a dose sufficient to promote viral clearance or eliminate Influenza A infected cells.

29 . A method for determining the presence of an Influenza virus infection in a subject, comprising the steps of:

(a) contacting a biological sample obtained from the subject with the antibody of claim 1 ;

(b) detecting an amount of the antibody that binds to the biological sample; and

(c) comparing the amount of antibody that binds to the biological sample to a control value, and therefrom determining the presence of the Influenza virus in the subject.

30 . A vaccine composition comprising the antibody of claim 1 or an epitope bound by the antibody of claim 1 .

31 . A diagnostic kit comprising the antibody of claim 1 .

32 . A prophylactic kit comprising the antibody of claim 1 or an epitope bound by the antibody of claim 1 .